Author

Evren Kocabaş Argon

Observed names: E. Kocabas Argon, Evren Kocabas Argon

Institution: BioNTech (United States)

Observed institutions: Epizyme (United States), Idera Pharmaceuticals (United States), BioNTech (United States)

OpenAlex ID: A5059566622

EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study

2022 · Marjorie G Zauderer, Peter W Szlosarek, et al. · The Lancet Oncology · 136

Safety and efficacy of tazemetostat, an enhancer of zeste-homolog 2 inhibitor, in patients with relapsed or refractory malignant mesothelioma.

2020 · Marjorie Glass Zauderer, Peter Wojciech Szlosarek, et al. · Journal of Clinical Oncology · 18

586P Safety of tazemetostat (TAZ) in combination with abiraterone/prednisone (A/P) or enzalutamide (E) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC)

2021 · W. Abida, N. Iannotti, et al. · Annals of Oncology · 3

A phase Ib/II open-label study of tazemetostat (TAZ) plus enzalutamide (E) or abiraterone/prednisone (A/P) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

2020 · Wassim Abida, Thomas Paul Bradley, et al. · Journal of Clinical Oncology · 3

Abstract 5659: Local treatment with novel TLR9 agonist IMO-2125 demonstrates antitumor activity in preclinical models of pancreatic cancer

2017 · Daqing Wang, Evren Kocabas Argon, et al. · Cancer Research · 3

Abstract CT170: Phase 1 study to characterize the pharmacokinetics and safety of tazemetostat in b-cell lymphomas or advanced solid tumors

2020 · Evren Kocabas Argon, Felicia Nguyen, et al. · Cancer Research · 2

Abstract 4704: Triple combination of IMO-2125, epacadostat and anti-PD-1 antibody demonstrates maximal antitumor efficacy and eradicates large established tumors in preclinical models

2018 · Evren Kocabas Argon, Fugang Zhu, et al. · Cancer Research · 2

BNT324-03: Phase 3, randomized, open-label trial of BNT324/DB-1311, a B7H3 ADC, versus docetaxel in patients with taxane-naïve metastatic castration-resistant prostate cancer (mCRPC).

2026 · Johann S. De Bono, Benjamin Garmezy, et al. · Journal of Clinical Oncology

Works count: 8

Citation count: 167

H-index: 3

I10-index: 2